Skip to main content

Lantern Pharma Inc.

corporate_fare Company Profile

Lantern Pharma Inc.

LTRN·NASDAQ·Life Sciences·CIK 0001763950

We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development. On average, our newly developed drug programs have been advanced from initial A.I. insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-$2.5 million per program. We have active clinical programs for our three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple important cancer indications, including both solid tumors and blood cancers. We have established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical development of our promising opportunities for central nervous system ("CNS") and brain cancers, many of which have no effective treatment options. We are also advancing an antibody-drug conjugate ("ADC") program focused on developing highly specific ADCs with highly potent drug-payloads. In January 2026, we introduced withZeta.ai - a generative AI platform purpose-built to empower researchers and clinicians to accelerate rare cancer research and drug development, dramatically improve research quality, and reduce R&D costs.

Lantern Pharma Inc. (NASDAQ:LTRN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for LTRN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Lantern Pharma Reports Q1 Results, Confirms $4.4M Offering, Warns of Going Concern and Short Runway
  • Lantern Pharma Plans AI Platform Spin-Off, Reports Reduced Q1 Loss and Clinical Milestones
  • Lantern Pharma Closes $4.4M Offering, Plans AI Platform Spin-Off
  • Director Buys $100K in Recent Offering, Signaling Confidence
  • Director Buys $100K in Lantern Pharma Offering

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$17.12M
Diluted EPS
-$1.57
Op. Cash Flow
-$15.68M
Free Cash Flow
-$15.68M
Operating Income
-$17.98M
Cash & Equivalents
$4.42M
Debt / Equity
0.00×
Shares Outstanding
11.25M sh
Source: 10-K · filed 2026-04-30 · accession 0001493152-26-019713
$0.23 -6.12% today
52-week range · as of 2026-11-18 $0.23 – $4.34
Market cap
$3.89M
Volume
238.5K (1.0× avg)
3-mo avg 246.6K
Live data · 2026-11-22 12:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LTRN - Filings & News (Page 2)

LTRN
May 15, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.81
Real-time Price: $0.230 info
Change: -$2.58 (-92%) info
Market Cap: $3.892M info
LTRN
May 15, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $3.14
Real-time Price: $0.230 info
Change: -$2.91 (-93%) info
Market Cap: $3.892M info
LTRN
May 14, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.19
Real-time Price: $0.230 info
Change: -$2.96 (-93%) info
Market Cap: $3.892M info
LTRN
May 14, 2026, 4:10 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $0.230 info
Change: -$2.87 (-93%) info
Market Cap: $3.892M info
LTRN
May 14, 2026, 4:10 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $0.230 info
Change: -$2.87 (-93%) info
Market Cap: $3.892M info
LTRN
May 14, 2026, 9:03 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.50
Real-time Price: $0.230 info
Change: -$2.27 (-91%) info
Market Cap: $3.892M info
LTRN
May 13, 2026, 8:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.05
Real-time Price: $0.230 info
Change: -$1.82 (-89%) info
Market Cap: $3.892M info
LTRN
Apr 10, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.87
Real-time Price: $0.230 info
Change: -$1.64 (-88%) info
Market Cap: $3.892M info
LTRN
Mar 30, 2026, 5:57 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.230 info
Change: -$0.820 (-78%) info
Market Cap: $3.892M info
LTRN
Mar 30, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.230 info
Change: -$1.01 (-81%) info
Market Cap: $3.892M info
LTRN
Jan 23, 2026, 7:31 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.46
Real-time Price: $0.230 info
Change: -$3.23 (-93%) info
Market Cap: $3.892M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets